Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages E1877-E1884

  Taniguchi, Hirokazu ^a   Tanisawa, Kumpei ^a   Sun, Xiaomin ^a   Cao, Zhen Bo ^a   Oshima, Satomi ^a   Ise, Ryuken ^a   Sakamoto, Shizuo ^a,b   Higuchi, Mitsuru ^a,b  

^a WASEDA UNIVERSITY   (Japan)

^b Institute of Advanced Active Aging Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; INSULIN;

ADULT; AGE; AGED; ARTICLE; BODY FAT DISTRIBUTION; CARDIORESPIRATORY FITNESS; DISEASE ASSOCIATION; ENDURANCE TRAINING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTRAABDOMINAL FAT; JAPANESE (PEOPLE); LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXYGEN CONSUMPTION; PREDICTION; PROTEIN BLOOD LEVEL; AGING; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; ENDURANCE; EXERCISE TEST; FITNESS; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY; RISK; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AGED; AGING; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; EXERCISE TEST; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ODDS RATIO; OXYGEN CONSUMPTION; PHYSICAL ENDURANCE; PHYSICAL FITNESS; RISK FACTORS; YOUNG ADULT;

EID: 84907610526     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1877     Document Type: Article

References (40)

1. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635.
2. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148:774-781.
3. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18:333-340.
4. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57:1246-1253.
5. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab. 2008;93:3627-3632.
6. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59:2781-2789.
7. Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology. 2012;153:69-80.
8. Chen C, Cheung BM, Tso AW, et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011;34:2113-2115.
9. Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013;36:145-149.
10. Fletcher JA, Meers GM, Laughlin MH, Ibdah JA, Thyfault JP, Rector RS. Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction. Appl Physiol Nutr Metab. 2012;37:1054-1062.
11. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med. 1999;130:89-96.
12. Sawada SS, Lee IM, Muto T, Matuszaki K, Blair SN. Cardiorespiratory fitness and the incidence of type 2 diabetes: prospective study of Japanese men. Diabetes Care. 2003;26:2918-2922.
13. La Monte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation. 2005;112:505-512.
14. Fox CS, Massaro JM, Hoffmann U, Pou KM, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48.
15. Tanisawa K, Ito T, Sun X, et al. High cardiorespiratory fitness can reduce glycated hemoglobin levels regardless of polygenic risk for type 2 diabetes mellitus in non-diabetic Japanese men. Physiol Genomics. 2014;46:497-504.
16. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492:203-206.
17. Lundasen T, Hunt MC, Nilsson LM, et al. PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 2007;360:437-440.
18. Heilbronn LK, Campbell LV, Xu A, Samocha-Bonet D. Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PLoS One. 2013;8:e78864.
19. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab. 2008;8:169-174.
20. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687-26695.
21. Ogawa Y, Kurosu H, Yamamoto M, et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA. 2007;104:7432-7437.
22. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J Cell Physiol. 2008;215:1-7.
23. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. βKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22:1006-1014.
24. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426-437.
25. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415-425.
26. Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26:271-281.
27. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71:369-375.
28. Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009;94:2151-2156.
29. Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev. 2006;7:183-200.
30. Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes (Lond). 2008;32(suppl 7):S83-S92.
31. Kralisch S, Tonjes A, Krause K, et al. Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J Endocrinol. 2013;216:135-143.
32. Cuevas-Ramos D, Almeda-Valdes P, Meza-Arana CE, et al. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One. 2012;7:e38022.
33. Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One. 2013;8:e63517.
34. Martin WH 3rd, Dalsky GP, Hurley BF, et al. Effect of endurance training on plasma free fatty acid turnover and oxidation during exercise. Am J Physiol. 1993;265:E708-E714.
35. Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2010;5:e15534.
36. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139:456-463.
37. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53:934-940.
38. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114:611-624.
39. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest. 1995;95:705-712.
40. Yan H, Xia M, Chang X, et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a crosssectional study. PLoS One. 2011;6:e24895.